MedTrace Logo

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

NCT04597437 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-07-28

No results posted yet for this study

Summary

ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.

Conditions

  • Dengue Fever

Interventions

DRUG

Zanamivir

Intravenous zanamivir

OTHER

Placebo

In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.

Sponsors & Collaborators

  • Naval Medical Research Center

    collaborator FED

  • Clinica de la Costa

    collaborator UNKNOWN

  • Global Disease Research

    collaborator UNKNOWN

  • Universidad Libre de Barranquilla

    collaborator UNKNOWN

  • George Washington University

    lead OTHER

Principal Investigators

  • Aileen Chang, MD · George Washington University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04597437 on ClinicalTrials.gov